The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Safey findings of EMERALD-1: durvalumab, bevacizumab and TACE in HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses the Phase III EMERALD-1 study (NCT03778957), which met its primary endpoint by demonstrating that durvalumab and bevacizumab with transarterial chemoembolization (TACE) significantly improved progression-free survival compared to placebo and TACE in patients with unresectable hepatocellular carcinoma. Whilst there were some concerns about addition of TACE in terms of safety, no additional hemorrhage-related adverse events were reported. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
